|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **myCAF** | **1****(TA010)** | **2****(TA011)** |  |  | **Average SLC7A11 Expression** |
| **SLC7A11 mRNA expression** | 439.4 | 834.1 |  |  | 636.8 |
| **Quiescent****PSC** | **1****(TA012)** | **2****(TA013)** |  |  | **Average SLC7A11 Expression** |
| **SLC7A11 mRNA expression** | 408.6 | 379.3 |  |  | 394.0 |
| **iCAF** | **1****(TA014)** | **2****(TA015)** | **3****(TA016)** | **4****(TA017)** | **Average SLC7A11 Expression** |
| **SLC7A11 mRNA expression** | 1122.0 | 1307.1 | 862.1 | 896.4 | 1046.9 |

**Supplementary Table 3: SLC7A11 is upregulated in iCAFS and myCAFs relative to normal pancreatic fibroblasts.** Summary of normalised SLC7A11 expression data from Ohlund et al (37) demonstrating higher average expression of SLC7A11 in immune-modulatory CAFs (iCAFs) and myofibroblast CAFs (myCAFs) relative to quiescent pancreatic fibroblasts (quiescent PSCs). Each column represents an independent culture of myCAFs, iCAFs or quiescent fibroblasts [refer to (37)].